Credit Agricole S A buys $124.6 Million stake in Amgen (AMGN)

Amgen (AMGN) : Credit Agricole S A scooped up 284,015 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 12, 2016. The investment management firm now holds a total of 817,788 shares of Amgen which is valued at $124.6 Million.Amgen makes up approximately 0.60% of Credit Agricole S A’s portfolio.

Other Hedge Funds, Including , Madison Investment Holdings Inc reduced its stake in AMGN by selling 23,869 shares or 17.06% in the most recent quarter. The Hedge Fund company now holds 116,060 shares of AMGN which is valued at $17.7 Million. Amgen makes up approx 0.38% of Madison Investment Holdings Inc’s portfolio.Ci Global Investments boosted its stake in AMGN in the latest quarter, The investment management firm added 647,931 additional shares and now holds a total of 693,106 shares of Amgen which is valued at $106.2 Million. Amgen makes up approx 2.63% of Ci Global Investments’s portfolio. Ironsides Asset Advisors added AMGN to its portfolio by purchasing 1,770 company shares during the most recent quarter which is valued at $271,146. Amgen makes up approx 0.03% of Ironsides Asset Advisors’s portfolio.

Amgen opened for trading at $148.92 and hit $151.71 on the upside on Friday, eventually ending the session at $150.18, with a gain of 1.02% or 1.51 points. The heightened volatility saw the trading volume jump to 30,76,109 shares. Company has a market cap of $112,817,769 M.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Citigroup Initiated Amgen on Feb 25, 2016 to “Neutral”, Price Target of the shares are set at $165.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.